Up a level |
2020
Hackl, Agnes, Erger, Florian ORCID: 0000-0002-2768-1702, Skerka, Christine, Wenzel, Andrea, Tschernoster, Nikolai, Ehren, Rasmus, Burgmaier, Kathrin, Riehmer, Vera, Licht, Christoph, Kirschfink, Michael, Weber, Lutz T., Altmueller, Janine, Zipfel, Peter F. and Habbig, Sandra (2020). Long-term data on two sisters with C3GN due to an identical, homozygous CFH mutation and autoantibodies. Clin. Nephrol., 94 (4). S. 197 - 207. DEISENHOFEN-MUENCHEN: DUSTRI-VERLAG DR KARL FEISTLE. ISSN 0301-0430
2019
Zhao, Fei, Afonso, Sara, Lindner, Susanne, Hartmann, Andrea, Loeschmann, Ina, Nilsson, Bo ORCID: 0000-0003-0057-2730, Ekdahl, Kristina N., Weber, Lutz T., Habbig, Sandra, Schalk, Gesa, Kirschfink, Michael, Zipfel, Peter F. and Skerka, Christine (2019). C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3-and C5-Convertases. Front. Immunol., 10. LAUSANNE: FRONTIERS MEDIA SA. ISSN 1664-3224
2017
Hackl, Agnes, Ehren, Rasmus, Kirschfink, Michael, Zipfel, Peter F., Beck, Bodo B., Weber, Lutz T. and Habbig, Sandra (2017). Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS. Pediatr. Nephrol., 32 (6). S. 1081 - 1088. NEW YORK: SPRINGER. ISSN 1432-198X
Kirschfink, Michael, Schick, Tina, Steinhauer, Marlin, Aslanidis, Alexander, Altay, Lebriz, Karlstetter, Marcus, Langmann, Thomas and Fauser, Sascha (2017). Local complement activation in aqueous humor in patients with age-related macular degeneration. Mol. Immunol., 89. S. 163 - 164. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 0161-5890
2014
Schalk, Gesa, Ehren, Rasmus, Vierzig, Anne, Kirschfink, Michael, Bergmann, Carsten, Hoppe, Bernd and Weber, Lutz Thorsten (2014). A Complicated Case Of Atypical Hemolytic Uremic Syndrom With Frequent Relapses Under Eculizumab. Pediatr. Nephrol., 29 (9). S. 1818 - 1819. NEW YORK: SPRINGER. ISSN 1432-198X
Wehling, Cyrill, Amon, Oliver, Bommer, Martin, Hoppe, Bernd, Kentouche, Karim, Schalk, Gesa, Weimer, Rolf, Wiesener, Michael, Tonshoff, Burkhard and Kirschfink, Michael (2014). Complement activation biomarkers under Eculizumab treatment in patients with atypical hemolytic-uremic syndrome (aHUS), membrano-proliferative glomerulonephritis (MPGN) and antibody-mediated renal graft rejection (AMR). Mol. Immunol., 61 (2). S. 259 - 260. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 0161-5890